Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 9, 2005. The report details specific corporate actions regarding share repurchases and changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to a specific share transaction:
- Shares Purchased: 730,000 Ordinary shares.
- Purchase Price: 1,363.18 pence per share.
- Treasury Shares Held: 95,558,000 shares (post-transaction).
- Shares in Issue: 5,848,070,265 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through a buyback program authorized at the Annual General Meeting on May 25, 2005. Additionally, the GSK Trust transferred 6,450 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991 on June 8, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports on the execution of the share buyback and the administrative transfer of trust shares.
Key Facts for Investor Verification
- Verify the total cost of the 730,000 share repurchase against the company's cash position in broader financial reports.
- Confirm the impact of the 95.5 million Treasury shares on earnings per share (EPS) calculations.
- Review the full Annual General Meeting minutes from May 25, 2005, to understand the remaining authority for future share buybacks.
- Note that three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold indirect interests via the GSK Trust.